Conventional doctors have considered chemotherapy treatment and radiation to be the standard of care for so long, they’ve lost sight of the fact that these treatments are causing cancer − not curing it. Did they somehow miss the fact that these super toxic cancer therapies could be the reason for their repeat customers?
As NousCom CEO Alfredo Nicosia likes to say, the Basel-based biotech is a relative fledgling at 2-years of age. But the core research team there has been working together for quite a few years.
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Alecensa (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
London startup developing holographic surgery headsets has raised $20m (£15m) from the backers of Facebook’s Oculus headset.
New research published in the journal BMC Cell Biology shows that old human cells can be rejuvenated using chemicals similar to resveratrol, which is a substance found in red wine and dark chocolate.
Existing digital health products hold the potential to save the nation $46 billion in healthcare spending if they’re deployed comprehensively, according to a new report from IQVIA, which on Tuesday renamed itself from Quintiles/IMS Health.
Cellectis (Alternext: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold, previously announced on September 4, 2017, on Phase 1 trials of Cellectis’ UCART123 product candidate in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
There is increasing evidence that the same mechanisms that cause depression in the brain can also affect other body systems as well. Here are seven physical symptoms that can be found alongside depression.
Machine learning technologies have already made huge strides in supporting the efforts of pharmaceutical companies in developing personalized medicines and novel biomarkers. This has been found to be helpful, notably for understanding the efficacy of prophylactic vaccines used for combating infectious diseases.
A lower dose formulation of Bayer and Janssen’s bloodthinner Xarelto has been approved by European regulators for preventing recurrent venous thromboembolism, expanding treatment options for patients.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.